A ccessory molecules play a role in the process of Ag recognition through two important functions: 1) enhancing adhesion of the T cell to the APC, allowing for more efficient TCR engagement; and 2) providing costimulation of T cells by transducing intracellular signals distinct from those mediated through the TCR. One of these accessory molecules is LFA-1 (␣ L /␤ 2 or CD11a/CD18) (1), a member of the ␤ 2 integrin family. LFA-1 is involved in a number of effector functions based on the specific cell in which it is expressed. LFA-1 is expressed in an inactive form on circulating PBLs, neutrophils, monocytes, granulocytes, and NK cells, and requires activation to bind to its ligands, ICAM-1, ICAM-2, or ICAM-3 (2, 3). The ␤ 2 family also consists of CD11b/CD18, CD11c/CD18, and CD11d/CD18, but LFA-1 is the only member of the ␤ 2 integrin family to be expressed on peripheral T cells. The physiological importance of LFA-1 is manifest in individuals lacking the ␤ 2 subunit in a disease known as leukocyte adhesion deficiency. Patients with this disease are characterized by an inability to clear pathogens, recurrent infections, and frequently, death at an early age unless treated with a bone marrow transplant (4, 5) . Furthermore, interference with LFA-1:ICAM-1 interactions has reduced the pathologic features of a number of autoimmune and inflammatory diseases, both in animal models and in human disease (6 -8) , although it is not clear in each case whether this involves alterations in lymphocyte homing, activation, or skewing. Therefore, understanding the role of LFA-1 in vivo is critical to understanding the implications of therapeutic interventions in LFA-1 function.
The role of LFA-1 as an adhesion molecule has been well described (3, 9) . LFA-1-mediated adhesion can facilitate Ag presentation to T cells (10 -15) . In addition to the known role of LFA-1 in T cell adhesion, there have been a number of reports that implicate LFA-1 in costimulation of T cells (16, 17) . We and others have assessed the role of LFA-1 in T cell activation using APC that were generated by gene transfer of class II and ICAM-1 into costimulation-negative cell lines (14, 15, 18 -20) . In these studies, it was found that Ag presentation by transfectants expressing class II and ICAM-1 can induce IL-2 secretion and proliferation in naive T cells, whereas transfectants expressing only class II cannot. In vitro, T cells from both CD11a Ϫ/Ϫ and CD18 Ϫ/Ϫ mice have been reported to have defects in activation under conditions requiring cell-cell interactions (e.g., mitogens and APC, MLRs), but have normal activation in cell contact-independent conditions, such as PMA/ionomycin and cross-linked anti-CD3 (21) (22) (23) . Despite in vitro evidence for the role of LFA-1 in CD4 ϩ T cell activation, it is not yet clear whether it is required for CD4 ϩ T cell activation in vivo. Activation in vivo occurs in the context of other costimulatory molecules and in the context of a three-dimensional matrix, both of which may combine to effectively compensate for the lack of LFA-1.
Evidence for contributions of LFA-1 to T cell function and migration in vivo has been provided through CD11a
Ϫ/Ϫ and CD18 Ϫ/Ϫ mice, as well as LFA-1-blocking studies. The interaction of LFA-1 with its ligands allows for improved adhesion of leukocytes to vascular endothelium, an essential step for the recruitment and migration of leukocytes into inflamed tissue (24, 25) . The peripheral lymph nodes (PLN) 3 of CD11a Ϫ/Ϫ mice have a substantial decrease in CD4 ϩ and CD8 ϩ T cells (26) . The high endothelial venules of these hypocellular lymph nodes (LN) have decreased adherent lymphocytes, and the residual lymphocyte entry occurs through ␣ 4 , ␣ 4 ␤ 7 , and VCAM-1 (26) . Both CD11a
and CD18
Ϫ/Ϫ mice demonstrate defects of T cell function in vivo, including in tumor rejection, delayed-type hypersensitivity (DTH) responses, and infectious responses (21, 22, (27) (28) (29) (30) (31) . Two studies attempted to better address whether there is a defect specifically in activation in vivo of LFA-1-deficient CD4 ϩ T cells using a DTH model; however, they arrived at opposite conclusions. One study examining CD11a
Ϫ/Ϫ mice concluded that T cell priming in the draining LN (DLN) was deficient (30) , while the other study using CD18
Ϫ/Ϫ mice concluded that T cell priming in the DLN was intact, and that the DTH response defect was secondary to a defect in T cell trafficking to the skin (31) . However, in analyzing these vivo responses, there are a number of complicating issues with regard to the ability to dissect the T cell-specific activation defect: 1) LFA-1 (and other ␤ 2 integrins) is expressed on multiple different hemopoietic cells; therefore, LFA-1 deficiency may be contributing to defects in the function of any of these cells, which ultimately contributes to a defect in T cell responses; 2) CD18 associates with ␣-chains other than CD11a, such that in the CD18 Ϫ/Ϫ mice, all the ␤ 2 integrins are defective, and therefore, the defects extend beyond that of LFA-1; and 3) the known dependency upon LFA-1 for T cell trafficking to LN and tissues results in a decreased number of T cells available to participate in the immune response, at the level of both priming and effector responses, which may well account for the T cell defects observed. Therefore, resolution of this issue requires a system that can restrict the LFA-1 defect to Ag-specific T cells and then track the migration and activation of these Ag-responsive T cells during an immune response.
To determine whether LFA-1-deficient CD4 ϩ T cells have an activation defect in vivo, we used the adoptive transfer of CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells into wild-type (WT) recipients. We found that in addition to the defect in trafficking to the PLN, CD18
Ϫ/Ϫ DO11.10 CD4 ϩ T cells have a defect in priming in DLN, which results in a functional deficit in IL-2, IFN-␥, and Ag-specific IgG2a production.
Materials and Methods

Mice
CD18
Ϫ/Ϫ mice were generously provided by A. Beaudet (Baylor College of Medicine, Houston, TX) (22) . CD18 Ϫ/Ϫ mice were backcrossed onto the BALB/c background (eight generations) and then to DO11.10 TCR transgenic mice. BALB/c mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and Charles River Laboratories (Wilmington, MA). T cells were phenotyped through staining of peripheral blood cells with a biotinylated mAb, KJ1-26 (Caltag Laboratories, Burlingame, CA), directed against the TCR clonotype expressed by DO11.10 T cells and by anti-CD18 (BD Pharmingen, San Diego, CA). Mice were maintained on autoclaved food and irradiated water in a specific pathogen-free facility in microisolator cages with filtered air, according to National Institutes of Health guidelines.
Cells
The transfectant into the fibrosarcoma cell line, 6132-PRO (Pro), expressing I-A d in combination with B7-1 (ProAd-B7), has been previously described (14, 32) . Cell lines were maintained in DMEM (Invitrogen Life Technologies, Gaithersburg, MD) supplemented with 10% FCS, 2 mM glutamine, 0.1 mM nonessential amino acids, 40 g/ml gentamicin, and 50 M 2-ME. G418 (200 g/ml) and MXH (6 g/ml mycophenolic acid, 250 g/ml xanthine, and 15 g/ml hypoxanthine) were added to the culture medium for maintenance of the transfectants.
Abs and staining reagents
Expression of transfected molecules was determined by flow cytometry using the anti-class II mAb, MKD6, and the anti-B7-1 mAb, 16-10A1 (American Type Culture Collection, Manassas, VA). The following Abs and secondary reagents used for flow cytometry were purchased from BD Pharmingen: PE-, FITC-, biotin-, and allophycocyanin-labeled anti-CD4; PE-and FITC-labeled anti-CD18; CyChrome-labeled streptavidin; PE-labeled anti-IL-2; and PE-labeled anti-IFN-␥. The following Abs and secondary reagents were purchased from Caltag Laboratories: PE-and biotinlabeled KJ1-26. Alkaline phosphatase-conjugated IgG2a was purchased from Southern Biotechnology Associates (Birmingham, AL).
In vivo T cell activation and migration
Spleen-derived CD4 ϩ T cells were isolated using CD4 ϩ microbeads, according to manufacturer instructions (Miltenyi Biotec, Auburn, CA). The efficacy of the CD4 ϩ T cell purification was monitored by flow cytometry and was routinely Ͼ93% pure. Freshly isolated ( 
Intracellular cytokine staining
Freshly isolated (2.5 ϫ 10 6 per mouse) CD18 ϩ/Ϫ or CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells were adoptively transferred by i.v. injection into WT BALB/c mice. Twenty-four hours later, mice were immunized s.c. with a mixture of 25 g of LPS/50 g of chicken OVA. DLN were harvested 5 days after immunization, and 1 ϫ 10 6 DLN cells were cocultured in 96-well round-bottom plates with 1 ϫ 10 5 ProAd-B7 in the absence or presence of 2 g/ml OVA peptide (323-339). Brefeldin A (Sigma-Aldrich) at 10 g/ml was added after 2 h, and cells were incubated for an additional 10 h. Cells were stained with anti-CD4 and KJ1-26, fixed with 3% paraformaldehyde, permeabilized with 0.3% saponin, and stained with anti-IL-2 or anti-IFN-␥ for 30 min. Cytokine production by KJ1-26 ϩ /CD4 ϩ cells was assessed, and isotype controls and stimulation with no peptide served as controls.
Measurement of chicken OVA-specific isotype Abs
Freshly isolated (2.5 ϫ 10 6 per mouse) CD18 ϩ/Ϫ or CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells were adoptively transferred by i.v. injection into WT BALB/c mice. Twenty-four hours later, mice were immunized s.c. with a mixture of 25 g of LPS/50 g of OVA. At weeks 1, 2, and 3 after immunization, serum was isolated from mice. Ninety-six-well plates (Costar, Cambridge, MA) were coated with OVA (50 g/ml) in PBS, and then blocked with PBS/5% FCS. Four dilutions of serum (1/100, 1/200, 1/400, 1/800) were incubated in the wells at 37°C ϫ 1 h. Plates were washed and incubated with IgG2a conjugated with alkaline phosphatase (Southern Biotechnology Associates). Plates were washed and incubated with phosphatase substrate (SigmaAldrich), and ODs were determined at 405 . 
In vitro T cell proliferation
Statistical analyses
Statistical comparisons of cell migration, cell accumulation, and OVAspecific IgG2a between treated groups were assessed using a one-tailed Student's t test. Values of p Ͻ 0.05 were considered significant.
Results
CD18
Ϫ
cells demonstrate defects in trafficking to and priming in the PLN
To investigate the role of LFA-1 in T cell activation in vivo, we generated CD18 Ϫ/Ϫ mice ϫ DO11.10 TCR transgenic mice that encode an OVA-specific, I-A d -restricted TCR. In light of the marked decrease in CD4 ϩ T cells in the PLN of LFA-1-deficient mice (26), the number of CD4 ϩ T cells available for priming during an immune response at this site is substantially decreased. It is not clear whether the T cells that successfully traffic to the PLN activate and develop an effector response equivalent to that of WT T cells. To eliminate the contribution of defective postactivation CD18
Ϫ/Ϫ T cell trafficking to nonlymphoid tissues, we focused on the priming of T cells within secondary lymphoid organs upon immunization. To avoid the influence of CD18 deficiency on non-T cell subsets, we used the adoptive transfer of CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells into WT mice, such that only the Ag-specific T cells migrating and responding to immunization will be LFA-1 deficient. These CD18 Ϫ/Ϫ CD4 ϩ peripheral T cells are deficient only in LFA-1, as it is the only ␤ 2 integrin expressed on peripheral CD4 ϩ T cells (data not shown). We isolated CD4 ϩ T cells from the spleen, as CD18 Ϫ/Ϫ mice have very few CD4 ϩ T cells in the PLN. To examine priming preferentially in the PLN, Ag was injected s.c. in the context of LPS as an adjuvant. To first assess whether the migration defect to PLN observed during homeostatic trafficking is still present under conditions of LPS/OVA injection, 2.5 ϫ 10 6 CD18 Ϫ/Ϫ CD4 ϩ D011.10 T cells were adoptively transferred into WT BALB/c mice, and 24 h later, the mice were immunized s.c. with LPS/OVA. Three hours after immunization, absolute numbers of migrated CD4 ϩ DO11.10 T cells to DLN were determined. Both CD18 ϩ/ϩ and CD18 ϩ/Ϫ mice have an identical cell surface expression of CD18 by flow cytometry, and CD18 ϩ/Ϫ mice are used as littermate controls for the CD18 Ϫ/Ϫ mice. An increase in the number of CD4 ϩ DO11.10 T cells is observed in the DLN after immunization in comparison with PBS controls (Fig. 1A) . However, migration of CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells to the DLN is decreased compared with CD18 ϩ/Ϫ CD4 ϩ T cells (Fig. 1A) , both in the absence and presence of LPS/OVA immunization. As expected, trafficking of CD18 Ϫ/Ϫ CD4 ϩ T cells is increased to the spleen compared with CD18 ϩ/Ϫ DO11.10 CD4 ϩ T cells, under these same conditions (Fig. 1B) . This is consistent with the splenic hypercellularity of CD4 ϩ T cells in LFA-1-deficient mice under homeostatic conditions (26) and most likely secondary to a redistribution of the CD4 ϩ T cell population due to the inability to properly traffic to LN.
In the context of the persistent migration defect of CD18
Ϫ/Ϫ CD4 ϩ T cells to DLN, we examined the activation upon s.c. LPS/ OVA immunization of those CD4 ϩ DO11.10 T cells that had successfully trafficked to the DLN of WT mice. Cell divisions, as indicated by CFSE dilution, 3 days after immunization were used as a measure of T cell activation. CD18
Ϫ/Ϫ DO11.10 CD4 ϩ T cells in DLN entered into cell division, but 25-40% less CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells in DLN were able to progress to later cell divisions as compared with CD18 ϩ/Ϫ DO11.10 CD4 ϩ T cells ( Fig.  2A) . To test whether the immune response was preferentially taking place in lymphoid tissues that were less impacted by the CD18 Ϫ/Ϫ trafficking defect, we examined the activation of CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells in spleen and MLN. Spleen demonstrated a higher number of CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells in the undivided peak ( Fig. 2A) , again indicative of less efficient T cell activation. The activated T cells observed in the spleen are a combination of local T cell activation due to Ag that has reached the spleen and of T cells activated in the DLN that have circulated to the spleen. There were very few CD18
ϩ/Ϫ and CD18 Ϫ/Ϫ T cells having undergone division in the MLN (Fig. 2A) .
Both CD18 ϩ/Ϫ and CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells that entered cell division demonstrated other markers of successful T cell activation, such as up-regulation of CD44 expression (data not shown). The defect in CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cell activation in the DLN persisted at days 5 and 7 after immunization, indicating that the defect is not simply a delayed kinetic response ( Fig. 2A) . As expected, the total number of accumulated CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells in the DLN at each of the time points assessed after immunization was also decreased relative to CD18 ϩ/Ϫ controls (Fig. 2B) . Therefore, CD18
Ϫ/Ϫ DO11.10 CD4 ϩ T cells demonstrate a persistent defect in both migration to the DLN and proliferation in the DLN in vivo upon s.c. immunization.
cells demonstrate a persistent defect in T cell priming despite cotransfer with CD18
ϩ/Ϫ
DO11.10 CD4 ϩ T cells
One possibility for the CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cell activation defect upon priming in the DLN is that the severe migration defect results in the lack of critical T cell mass necessary for optimal T cell proliferation. If an adequate number of cells migrating and Ϫ/Ϫ DO11.10 CD4 ϩ T cells revealed a similar defect in reaching the later cell divisions (Fig. 3A) compared with CD18
ϩ/Ϫ CD4 ϩ T cells as when transferred alone ( Fig.  2A) . As expected, there was also a defect in accumulation of Agspecific CD18
Ϫ/Ϫ CD4 ϩ T cells (Fig. 3B) . Therefore, despite the presence of a normally dividing CD4 ϩ DO11.10 T cell population, CD18
Ϫ/Ϫ CD4 ϩ T cells continue to demonstrate a proliferation defect.
CD18
Ϫ/Ϫ DO11.
CD4 ϩ T cells demonstrate defects in production of IL-2 and IFN-␥ upon priming in the LN
In light of the defect in proliferation observed in CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells upon LN priming, we assessed whether there was a defect in IL-2 production. WT mice were adoptively transferred with CD18 ϩ/Ϫ or CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells and immunized s.c. 24 h later with LPS/OVA. DLN were harvested 5 days after immunization and cocultured in vitro with OVA peptide and APC (ProAd-B7) that provide for Ag-specific, LFA-1-independent activation (see Fig. 7C ). The APC were generated from a costimulatory-negative fibrosarcoma cell line (6132-PRO) that was transfected with the class II Ag, I-A d , in combination with the well-documented costimulatory molecule, B7-1 (ProAd-B7) (14) . The decreased number of CD18 Ϫ/Ϫ DO11.10 CD4
ϩ T cells present in the DLN would be expected to result in a decreased level of cytokine secretion into the supernatant of whole LN preparations. Therefore, we used intracellular cytokine staining to determine the percentage of DO11.10 CD4 ϩ T cells producing IL-2. A decreased percentage of CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells produced IL-2 (ϳ33%) in comparison with CD18 ϩ/Ϫ T cells (ϳ75%) (Fig. 4) . Costimulation through LFA-1 has been shown to result in Th1 skewing (33) (34) (35) (36) . In addition, T cell production of IFN-␥ is known to require adequate progression into cell division (37) . We therefore assessed IFN-␥ production by CD18
Ϫ/Ϫ DO11.10 CD4 ϩ T cells after priming in LN. Consistent ϩ/Ϫ T cells, 25-40% less CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells progressed into the later cell divisions in DLN on day 3. Correspondingly, CD18 ϩ/Ϫ T cell accumulation ranged from 2.5-to 7.5-fold greater than that of CD18 Ϫ/Ϫ T cells on day 3, 3-to 11-fold greater on day 5, and 6-to 13-fold greater on day 7. The data are representative of three mice per condition. The data represent two independent experiments on the full time course, and at least an additional two independent experiments at day 3. ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001.
with previously published reports, ϳ6% of CD18 ϩ/Ϫ DO11.10 CD4 ϩ T cells secrete IFN-␥ in the DLN (38) . However, a decreased percentage of CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells produced IFN-␥ (ϳ1%) in comparison with CD18 ϩ/Ϫ T cells (ϳ6%) (Fig.  4) . Therefore, the defect in priming of CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells in LN results in defects in production of IL-2 and IFN-␥ upon restimulation.
cells demonstrate a defect in T cell-dependent IgG2a isotype switching upon s.c. immunization
OVA-specific IgG2a production upon s.c. immunization of BALB/c mice with LPS/OVA requires the presence of adoptively transferred DO11.10 CD4 ϩ T cells that secrete IFN-␥ in the DLN (39) . For the production of other OVA-specific isotype Abs, such as IgG1, the presence of endogenous BALB/c T cells is sufficient (39) . In light of the defect in CD18
Ϫ/Ϫ DO11.10 CD4 ϩ T cell proliferation and IFN-␥ production upon s.c. LPS/OVA immunization, we sought to determine whether this had a functional effect on T cell-dependent OVA-specific IgG2a isotype switching. WT mice were adoptively transferred with CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells and immunized 24 h later with s.c. LPS/OVA, and OVAspecific IgG2a was assessed at 1-wk intervals for 3 wk. In comparison with CD18 ϩ/Ϫ controls, mice receiving CD18
DO11.10 CD4
ϩ T cells demonstrated a persistent significant defect in isotype switching to OVA-specific IgG2a (Fig. 5) .
cells demonstrate a severe defect in T cell priming upon i.v. immunization
We considered the possibility that the activation defect observed by CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells upon LN priming might still be related to the migration defect to LN. One consideration would be that the activation defect might reflect a selection bias in the subset of CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells that do successfully traffic to the PLN. For example, the 10 -20% subset of CD18 Ϫ/Ϫ
CD4
ϩ T cells successfully trafficking to the PLN do so through ␣ 4 , ␣ 4 ␤ 7 , and VCAM-1 (26) . As demonstrated in the migration studies above, CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells do not have a defect in migration to the spleen, and in fact, have a relative increase in the trafficking to spleen (Fig. 1B) . Therefore, examining the priming of CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells in the spleen eliminates potential secondary consequences of the trafficking defect contributing to the T cell activation defect observed upon priming in LN, such as the possibility of a subset bias effect as well as the critical mass effect addressed in the cotransfer experiments (Fig. 3) ϩ/Ϫ T cells. Again, this defect persists over 7 days, such that it is not merely one of delayed kinetics (Fig. 6A) . Furthermore, compensatory T cell activation does not take place in other secondary lymphoid structures (Fig. 6A) . CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells that undergo cell divisions also up-regulate CD44 as a marker of T cell activation (data not shown). The defect in cell division correlates to a substantial decrease in the absolute number of CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells present in the spleen at each of the time points assessed (Fig. 6B) . This is observed even at the early 3-day time point, despite the increased number of CD18 Ϫ/Ϫ CD4 ϩ T cells present at the onset of activation in light of the enhanced migration to spleen (Fig. 1B) . Therefore, despite an initial migration advantage to the spleen, CD18 Ϫ/Ϫ
DO11.10 CD4
ϩ T cells demonstrate a severe persistent defect in entry and progression into cell division upon splenic priming that is associated with a significant decrease in accumulation of Ag-specific CD4 ϩ T cells.
DO11.10 CD4 ϩ T cells from CD18
Ϫ/Ϫ mice demonstrate defects in Ag-specific activation with WT spleen-derived APC One possible mechanism for the CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cell activation defect is at the level of T cell:APC interactions. Agdependent activation of LFA-1-deficient CD4 ϩ TCR transgenic T cells has not been reported. To determine whether CD18 Ϫ/Ϫ
DO11.10 CD4
ϩ T cells were defective in activation upon Ag presentation with spleen-derived APC, we assessed their activation upon coculture with WT irradiated splenocytes. CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells had a substantial defect in activation when Ag was presented by splenocytes (Fig. 7A) . As dendritic cells (DC) are highly effective APC, and are most likely the APC involved in priming CD4 ϩ T cells in the secondary lymphoid organs, we examined whether purified DC harvested from spleen demonstrated a dependency upon LFA-1:ICAM-1 for efficient Ag-dependent activation of T cells. DC were harvested from the spleen of mice treated in vivo with LPS to simulate the source and stimulation conditions of the DC involved in the in vivo i.v. priming experiments. CD18
Ϫ/Ϫ DO11.10 CD4 ϩ T cells demonstrate a significant defect in activation upon stimulation with Ag by spleen-derived CD11c-purified DC (Fig. 7B) . As expected, the DC were much more effective at activating CD4 ϩ T cells on a per cell basis than was whole spleen (Fig. 7, A and B) . The activation defect upon Ag presentation using splenocyte-derived APC may be an intrinsic activation defect in CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells due to abnormal development, or an LFA-1-specific defect. We addressed this issue by using ProAd-B7 as APC, thereby providing for a system that is CD18 independent, but Ag and cell contact dependent. We find that CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells do not have an intrinsic defect in T cell activation, with activation equal to that of WT T cells upon presentation with Ag by ProAd-B7 (Fig. 7C) . Therefore, CD18
Ϫ/Ϫ DO11.10 CD4 ϩ T cells exhibit a substantial defect in activation upon Ag presentation by WT splenocytes and DC, thereby accounting for at least one of the mechanisms contributing to the deficient proliferation of CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells.
Discussion
The ability to dissect whether LFA-1 on CD4 ϩ T cells plays a role in priming in vivo has been confounded by: 1) the importance of LFA-1 for T cell trafficking to PLN, and 2) the presence of LFA-1 on other hemopoietic cells, including the APC involved in T cell priming. Using an Ag-specific T cell activation system with transfer of CD4 ϩ DO11.10 responder CD18 ϩ/Ϫ or CD18 Ϫ/Ϫ T cells into WT mice, we have defined that in addition to the role LFA-1 plays in migration of CD4 ϩ T cells to LN, it is required for optimal priming of CD4 ϩ DO11.10 T cells. This defect in CD4 ϩ T cell priming is not secondary to a defect in critical mass, as it occurs even when initial T cell activation takes place in the context of adequate CD4
ϩ responder T cells. In addition, the defect in priming is not due to a population bias secondary to selective trafficking, as it also occurs in secondary lymphoid structures where there is no trafficking deficit. Consequences of the impaired CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cell trafficking and priming in the LN include a defect in IL-2 and IFN-␥ production along with a persistent defect in serum OVA-specific IgG2a. One mechanism contributing to the Ag-specific priming defect is at the level of T cell:APC interactions.
The defect in progression of CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells to later cell divisions can result in certain defects in effector outcome. One such outcome is IFN-␥ production (37) . A number of studies have shown in vitro that stimulation of T cells in the context of LFA-1 results in enhanced Th1 skewing (33) (34) (35) (36) . Other reports have argued that this outcome depends upon the dose of Ag (40) . Reports in vivo demonstrating decreased cytokine secretion in whole ex vivo LN preparations are confounded by the decreased number of T cells present (28), with an inability to identify cytokine secretion of Ag-specific T cells on a per cell basis. Our study demonstrates that CD18 The different routes of immunization in our study demonstrate varying degrees of CD18 Ϫ/Ϫ T cell proliferation defects. Ϫ/Ϫ CD4 ϩ T cells enter into cell division in the spleen, and the progression through cell division is further decreased such that the majority of cells do not progress beyond three cell divisions. The contrast in the severity of the s.c. and i.v. immunization CD18 Ϫ/Ϫ T cell proliferation defect relative to CD18 ϩ/Ϫ T cells is also observed in the PLN, arguing that the effect is not simply secondary to the lymphoid structure in which the activation is taking place, but rather the route of immunization. One possibility for this differential outcome is that the DC presenting Ag under i.v. immunization conditions have increased requirements for LFA-1: ICAM-1 interactions during T cell activation in comparison with the tissue-derived DC recruited upon s.c. immunization. ICAM-1 expression increases with DC maturation, and the expression varies based on the DC maturation stimulus (36) . ICAM-1 levels are known to vary on different DC subsets (41 CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells demonstrate a decrease in accumulation of Ag-specific T cells after priming both in LN and in the spleen. This may be due to one or more of the following: 1) decreased initial T cell migration; 2) decreased proliferation; 3) increased apoptosis; or 4) increased egress. Decreased proliferation most likely contributes to a decreased number of antigenicspecific CD18 Ϫ/Ϫ T cells upon priming in both LN and spleen. In contrast, decreased migration contributes to the decrease in the number of Ag-specific CD18 Ϫ/Ϫ CD4 ϩ T cells only in the LN, as there is actually enhanced migration of CD18 Ϫ/Ϫ CD4 ϩ T cells to the spleen. Whether costimulation through LFA-1 also contributes to rescue from cell death and/or a prevention of T cell egress upon Ag activation in vivo is not known. Depending on the conditions, stimulation through LFA-1 has been reported to be both proapoptotic (42, 43) and antiapoptotic (44) in T cells. Stimulation of T cells through the TCR in the absence of a costimulatory signal often results in cell death. However, in vitro, costimulation through LFA-1 alone is not sufficient to rescue from the cell death (18, 45) . The role of LFA-1 in T cell apoptosis under conditions of Ag activation in vivo is not known. LFA-1 has been shown to contribute to the retention of lymphocytes in the lung (46) ; however, whether LFA-1 contributes to lymphocyte retention in the LN, through, for example, the down-regulation of sphingosine-1-phosphate receptor on lymphocytes in the LN (47), is not known. Therefore, the absence of LFA-1 on DO11.10 CD4 ϩ T cells during i.v. and s.c. immunization results in a decreased accumulation of Ag-specific T cells, which is most likely a combination of defects in migration (s.c. immunization) and proliferation (i.v. and s.c. immunization), as well as possibly in cell death and lymphoid organ egress.
Considerations of mechanisms accounting for the CD18
Ϫ/Ϫ
CD4
ϩ T cell activation defect may include both adhesive and costimulatory functions of LFA-1. First, the absence of adhesion provided by LFA-1 may result in a failure of CD4 ϩ T cells: 1) to properly localize to the appropriate region of secondary lymphoid structures; or 2) to form T cell:APC conjugates. Second, in the absence of costimulation provided by LFA-1, CD4 ϩ T cells may not: 1) appropriately initiate distinct LFA-1-dependent signaling pathways; or 2) initiate necessary structural rearrangements at the level of intracellular scaffolding, enabling efficient assembly of signaling molecules, or at the level of the organization of the immunological synapse (48, 49) . The improper localization of LFA-1-deficient T cells is a less likely factor, as previous studies examining localization of cells by immunohistochemistry within the white pulp of the spleen demonstrate a minimal inhibition in localization of B and T cells upon blocking LFA-1 interactions or in the absence of CD18, unless trafficking was also blocked by anti-␣ 4 ␤ 1 (50, 51) . In addition, H&E sections of the spleen and LN in our mice demonstrate intact architecture with proper T cell zone segregation, despite the hypocellularity of the PLN and histiocytic expansion of the sinusoidal regions (data not shown). Furthermore, the in vitro studies eliminate the issue of proper T cell localization as a sole mechanism for the T cell activation defect by directly coculturing T cells and APC. These studies show a clear CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cell activation defect upon Ag presentation by irradiated splenocytes (Fig. 7A ) and spleen-derived CD11c-purified DC (Fig. 7B) . Therefore, despite the potency of DC as APC, they clearly depend upon LFA-1:ICAM-1 interactions for optimal DO11.10 CD4 ϩ T cell activation (Fig. 7B ). In conclusion, these studies demonstrate that in addition to the migration defect to PLN upon s.c. immunization, CD18 Ϫ/Ϫ DO11.10 CD4 ϩ T cells have a defect in progression through cell division and are defective in production of IL-2 and IFN-␥ as well as OVA-specific IgG2a.
